Roche Holding AG (RHHBY)
OTCMKTS · Delayed Price · Currency is USD
59.35
+0.17 (0.29%)
At close: Feb 20, 2026
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$773,849
Profits / Employee
$157,320
Market Cap
378.54B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| OpGen | 1 |
Roche Holding AG News
- 19 hours ago - Roche (RHHBY) Awaits FDA Decision on Giredestrant for Breast Cancer - GuruFocus
- 20 hours ago - Roche granted FDA review for novel breast cancer therapy - Seeking Alpha
- 21 hours ago - FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer - Benzinga
- 1 day ago - FDA Approves Genentech's Venclexta And Acalabrutinib Combo For Untreated CLL - Nasdaq
- 1 day ago - FDA Approves Genentech's Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia - Business Wire
- 1 day ago - FDA Accepts New Drug Application for Genentech's Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer - Business Wire
- 1 day ago - FDA accepts New Drug Application for Roche's giredestrant in ESR1-mutated, ER-positive advanced breast cancer - GlobeNewsWire
- 4 days ago - Change to the Roche Enlarged Corporate Executive Committee - GlobeNewsWire